Scarica l'app Stockscreener
39.89
1.29%
-0.52
Precedente Chiudi:
$40.41
Aprire:
$40.92
Volume 24 ore:
844.85K
Relative Volume:
1.15
Capitalizzazione di mercato:
$3.13B
Reddito:
$688.00K
Utile/perdita netta:
$-135.82M
Rapporto P/E:
-19.20
EPS:
-2.078
Flusso di cassa netto:
$-169.41M
1 W Prestazione:
-0.65%
1M Prestazione:
+8.90%
6M Prestazione:
+154.89%
1 anno Prestazione:
+121.24%
Intervallo 1D:
$39.00
$42.40
Intervallo di 1 settimana:
$39.00
$42.93
Portata 52W:
$10.91
$45.76
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
39.89 | 3.13B | 688.00K | -135.82M | -169.41M | -2.078 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Transcript : Spyre Therapeutics, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08 - marketscreener.com
Market Review: Is RBNE stock risky to hold now2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Globe and Mail
Weekly Earnings: What is the implied volatility of Spyre Therapeutics IncMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn
Patterns Watch: Can Spyre Therapeutics Inc grow without external fundingMarket Trend Review & Technical Confirmation Trade Alerts - baoquankhu1.vn
Trading Recap: Can Spyre Therapeutics Inc deliver consistent EPS growthVolume Spike & Weekly Top Performers Watchlists - baoquankhu1.vn
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - AOL.com
New Spyre hires get 46,600 stock options at $42.49 strike - Stock Titan
[EFFECT] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns - Yahoo Finance
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - GuruFocus
Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CEO sells 15,000 shares in Rule 10b5-1 plan - Stock Titan
Investment Review: Is Spyre Therapeutics Inc a top pick in the sectorPortfolio Return Report & Verified Entry Point Signals - baoquankhu1.vn
Spyre Therapeutics CEO Sells 15,000 Shares - TradingView
Support Test: Can Spyre Therapeutics Inc lead its sector in growthPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Aug Analyst Calls: Can Spyre Therapeutics Inc lead its sector in growth - baoquankhu1.vn
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre The - GuruFocus
Morgan Stanley broker lists 60,000-share SYRE resale (SYRE) - Stock Titan
SYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SYRE PE Ratio & Valuation, Is SYRE Overvalued - Intellectia AI
Spyre Therapeutics, Inc. (SYRE): Investor Outlook Amid A 35% Potential Upside - DirectorsTalk Interviews
[POS AM] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. targets breakthrough in inflammatory bowel disease with combination therapies - Traders Union
Spyre reports enhanced efficacy of anti-TL1A and anti-IL-23 combination - bioworld.com
Assessing Spyre Therapeutics (SYRE) Valuation After A Powerful Multi‑Period Share Price Run - simplywall.st
Insider Sell: Can Spyre Therapeutics Inc maintain sales growthTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Spyre Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Bull Bear: Is Spyre Therapeutics Inc a top pick in the sector2025 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
SYRESpyre Therapeutics Latest Stock News & Market Updates - Stock Titan
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating - marketscreener.com
Wells Fargo & Company Forecasts Strong Price Appreciation for Spyre Therapeutics (NASDAQ:SYRE) Stock - Defense World
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Spyre Therapeutics (SYRE) and Tandem Diabetes Care (TNDM) - The Globe and Mail
Gains Report: Can Spyre Therapeutics Inc. (3920) stock surprise markets with earningsMarket Sentiment Summary & Free Fast Entry Momentum Trade Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Organigram Global (OGI) and Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre Therapeutics (NASDAQ:SYRE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Spyre Therapeutics stock hits 52-week high at 42.93 USD - Investing.com India
Spyre Therapeutics (SYRE) Buy Rating Reiterated by BTIG | SYRE S - GuruFocus
Spyre Therapeutics stock hits 52-week high at 42.93 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics Stocks Surge Amid Cash Flow and Research Developments - timothysykes.com
How buybacks impact Spyre Therapeutics Inc. stock valueInflation Watch & Weekly Watchlist for Hot Stocks - mfd.ru
Spyre Therapeutics Surprises with Strong Q4 Despite Losses - StocksToTrade
Wells Fargo Raises Price Target for Spyre Therapeutics (SYRE) to $50 | SYRE Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price - MarketBeat
Spyre Therapeutics Stock Jumps on Pipeline Momentum - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3%Time to Buy? - MarketBeat
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):